ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0796

Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases

Carlos Raul Ramirez Medina1, Mark Lunt2, David Jenkins2, William Dixon2, Niels Peek3 and Meghna Jani2, 1The University of Manchester, Warrington, United Kingdom, 2University of Manchester, Manchester, United Kingdom, 3THIS Institute , University of Cambridge, Cambridge, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Biostatistics, fibromyalgia, Outcome measures, pain, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe’s highest opioid-related hospital admissions. Patients with Rheumatic and Musculoskeletal Diseases (RMDs) are especially at risk due to multimorbidity and long-term opioid use. Machine learning-based clinical prediction models (CPMs) could improve risk assessment in this context by addressing nonlinear relationships. We aimed to develop and evaluate CPMs based on regression and ML, using nationally representative UK data, to estimate the risk of opioid-related hospitalizations in RMD patients for non-cancer pain.

Methods: We conducted a retrospective cohort study using the Clinical Research Practice Datalink, a large UK primary care electronic health record database, from 2006-2021. Patients included were new opioid users aged ≥18 years old with one or more RMDs (osteoarthritis, fibromyalgia, rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, or psoriatic arthritis). Patients with a history of cancer were excluded. Opioid-related hospital admissions (any admission code including opioid poisoning, fractures, falls, delirium, sleep disorders and constipation) were identified using Hospital Episode Statistics Admitted Patient Care and Accident and Emergency Attendances. Candidate predictors were selected based on clinical relevance from prior literature. Patients were considered ‘at risk’ from their first new opioid prescription and were censored at first admission, death, loss of follow-up or after two years without opioid prescription. CPMs using Cox proportional hazards (CPH) and Random Survival Forest were trained with time-to-event patient data. Predictive performance was evaluated by calculating the area under the receiver characteristic operator curve (AUC) using 5-fold cross validation.

Results: Over a 15-year period, 1,070,719 unique patients (59.5% female, median age [IQR]: 62 [25]) were new opioid users diagnosed with one or more RMDs. Opioid-related hospitalization occurred in 43,728 patients (4.1%). In the CPH model, top risk factors for opioid-related hospitalization included alcohol dependence (hazards ratio [HR]: 2.45, 95% CI: 2.28 – 2.64), history of suicide attempts and self-harm (HR: 2.04, 95% CI:1.89 – 2.20) and history of substance abuse (HR: 1.27, 95% CI:1.14 – 1.43). Concomitant use of benzodiazepines and gabapentinoids were associated with 24% (HR: 1.24, 95% CI 1.21 – 1.26) and 18% (HR: 1.18, 95% CI 1.14 – 1.21) higher risks, respectively. Obesity and MME at initiation lacked statistical significance. Permutation importance highlighted antipsychotic and antidepressant use as top risk factors. The CPH and Random Survival Forest models achieved AUC values of 0.71 (95% CI: 0.70-0.72) and 0.68 (95% CI: 0.67-0.69), respectively.

Conclusion: The CPM based on CPH achieved better discrimination than the Random Survival Forest. Higher risks of opioid-related hospitalization were associated with concomitant use of benzodiazepines and gabapentinoids, prior alcohol dependence, and history of self-harm. Greater vigilance where these factors exist could guide targeted interventions to reduce opioid-related hospitalizations

Supporting image 1

Figure 1. Time-dependent AUC curves of Cox proportional hazards (CPH) and Random Forest with maximally selected rank statistics (MSR-RSF) models.


Disclosures: C. Ramirez Medina: None; M. Lunt: None; D. Jenkins: None; W. Dixon: Google, 2; N. Peek: None; M. Jani: None.

To cite this abstract in AMA style:

Ramirez Medina C, Lunt M, Jenkins D, Dixon W, Peek N, Jani M. Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/development-and-evaluation-of-machine-learning-prediction-models-for-hospitalizations-due-to-opioid-related-harms-among-new-users-with-rheumatic-and-musculoskeletal-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-evaluation-of-machine-learning-prediction-models-for-hospitalizations-due-to-opioid-related-harms-among-new-users-with-rheumatic-and-musculoskeletal-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology